Foghorn Therapeutics Ownership
| FHTX Stock | USD 4.34 0.36 9.05% |
Shares in Circulation | First Issued 2017-12-31 | Previous Quarter 51.6 M | Current Value 62.6 M | Avarage Shares Outstanding 33.3 M | Quarterly Volatility 12 M |
Foghorn |
Foghorn Stock Ownership Analysis
About 19.0% of the company shares are held by company insiders. The company recorded a loss per share of 1.85. Foghorn Therapeutics had not issued any dividends in recent years. Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Foghorn Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 119 people. To learn more about Foghorn Therapeutics call Adrian Gottschalk at 617 586 3100 or check out https://foghorntx.com.Besides selling stocks to institutional investors, Foghorn Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Foghorn Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Foghorn Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Foghorn Therapeutics Quarterly Liabilities And Stockholders Equity |
|
Foghorn Therapeutics Insider Trades History
About 19.0% of Foghorn Therapeutics are currently held by insiders. Unlike Foghorn Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Foghorn Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Foghorn Therapeutics' insider trades
Foghorn Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Foghorn Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Foghorn Therapeutics backward and forwards among themselves. Foghorn Therapeutics' institutional investor refers to the entity that pools money to purchase Foghorn Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Alphabet Inc | 2024-09-30 | 500.9 K | Point72 Asset Management, L.p. | 2024-09-30 | 399.7 K | Birchview Capital, Lp | 2024-09-30 | 320.9 K | Northern Trust Corp | 2024-09-30 | 250.8 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 129.3 K | Sio Capital Management, Llc | 2024-09-30 | 121.7 K | Morgan Stanley - Brokerage Accounts | 2024-09-30 | 108.2 K | Citadel Advisors Llc | 2024-09-30 | 81.2 K | Charles Schwab Investment Management Inc | 2024-09-30 | 75.5 K | Flagship Ventures Management, Inc. | 2024-09-30 | 12.7 M | Fmr Inc | 2024-09-30 | 6.3 M |
Foghorn Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Foghorn Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Foghorn Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Foghorn Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Foghorn Therapeutics Outstanding Bonds
Foghorn Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Foghorn Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Foghorn bonds can be classified according to their maturity, which is the date when Foghorn Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Foghorn Therapeutics Corporate Filings
8K | 24th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of October 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 24th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
F3 | 4th of September 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Foghorn Stock Analysis
When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.